Greer Laboratories, Inc.

Greer Laboratories, Inc., doing business as Stallergenes Greer, manufactures allergen extract biological products, diagnostic testing antigens, and related medical supplies as a prime contractor to the Defense Health Agency and Department of the Army Medical Command, competing exclusively under full-and-open contracting with no set-aside designations. The company is a foreign-owned, for-profit manufacturer headquartered in Lenoir, North Carolina, and has been registered in the System for Award Management since 2002.

Greer's federal customer concentration sits almost entirely within military and Department of Veterans Affairs healthcare: the Defense Health Agency and the Department of the Army Medical Command anchor 18 percent of all awards but account for approximately $61.6 million of the $62.2 million combined potential value across all 265 prime awards in the source data. The two customers are effectively co-equal in dollar exposure — the Army Medical Command holds $31.5 million in potential value across 18 awards, and the Defense Health Agency holds $30.1 million across 19 awards — with marginal contribution from the Department of Veterans Affairs, the Department of the Navy, and the National Institutes of Health. Greer's primary mission is supplying the U.S. Army Centralized Allergen Extract Laboratory at Fort Meade, Maryland, which processes approximately 100,000 vials of allergy vaccines and diagnostics annually in support of over 500 military and VA medical facilities.

Greer holds a multi-year indefinite delivery vehicle portfolio with the Defense Health Agency and Army. The primary single-award IDC (W91YTZ17D0007, $9.3 million across 4 task orders) runs through February 2028 and supplies allergen extract vaccines to Fort Meade. A second single-award IDC (valued at $12.0 million, awarded September 22, 2025, ultimate completion September 21, 2030) represents a new five-year contract structured with a $1.8 million base year and four option years, demonstrating customer confidence in continuity of supply. Additional IDCs under Army control (W91YTZ07D0006, $2.7 million; W91YTZ12D0022, $3.5 million; W81K0423D0004, $1.3 million) bring the total parent-vehicle footprint to at least $29.8 million. Representative delivery orders include a $1.09 million firm fixed-price order (June 4, 2025, completion December 3, 2025), a $685,882 order (June 6, 2025, completion June 20, 2025), and a $455,291 order (September 30, 2026, completion September 30, 2026).

Recent activity has averaged 5 awards per year from 2023 through 2026, with only one award carrying an ultimate completion date within the next twenty-four months ($455 thousand, September 30, 2026), indicating mature contract execution with extended option-year leverage. The vendor competes in a highly specialized niche — allergen extract biologics manufacturing — categorized across Pharmaceutical Preparation Manufacturing (41 awards), Biological Product Manufacturing (8 awards), and In-Vitro Diagnostic Substance Manufacturing (4 awards), with PSC codes concentrated in Drugs and Biologicals (137 awards) and Medical and Surgical Instruments (62 awards). FDA approval and United States Pharmacopeia 797 compliance are core procurement mandates, and solicitations explicitly require suppliers to source at least 80 to 98 percent of requested extracts without substitutions, positioning Greer as a single-source or near-sole-source supplier to military allergy care.